Clinical Trial Update: Lorlatinib in ROS1+ NSCLC With Brain Metastasis [Phase 2]

View source ↗

Summary

Lorlatinib is being studied in a Phase 2 trial for ROS1-positive non-small cell lung cancer with brain metastases, which is currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Non-small Cell Lung Cancer

Drugs mentioned

• Lorbrena (lorlatinib)

Snippet

Sponsor: Hunan Cancer Hospital | Conditions: Lung Cancer (NSCLC) | Phase 2 | Status: NOT_YET_RECRUITING